Scientists found a compound that made mice burn more energy and lose fat without significant muscle loss.
Date: August 23, 2026 Source: University of California - Berkeley Summary: A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. Share: Facebook Twitter Pinterest LinkedIN Email FULL STORY A compound called TOFA helped obese mice burn more energy, lose fat while preserving muscle, and improve blood sugar, triglycerides, and fatty liver disease. Credit: ShutterstockGLP-1 medications have transformed the treatment of obesity, diabetes, and fatty liver disease over the past several years. Drugs sold as Ozempic, Wegovy, Mounjaro, and Zepbound can produce substantial weight loss while helping patients control blood sugar.
But these medications can also cause problems. Some patients experience nausea and other gastrointestinal side effects. Because GLP-1 drugs reduce appetite and food intake, they may also contribute to nutritional deficiencies and loss of muscle, potentially increasing the risk of frailty and other long-term health issues.
Researchers at UC Berkeley are now investigating a very different strategy for treating obesity and diabetes. Instead of reducing the amount of energy a person consumes, their approach is designed to increase the amount of energy the body uses by raising metabolic activity.
A Different Way to Target Weight Loss
In a study published August 21 in Science Advances, the team reports that a molecular compound called 5-tetradecyloxy-2-furoic acid (TOFA) can interfere with the production of lipids such as cholesterol and triglycerides. At the same time, it activates genes that encourage cells to use fat for fuel and produce more energy.
In experiments with mice, TOFA improved insulin sensitivity and glucose control, reduced triglyceride levels, and improved signs of fatty liver disease. Obese mice treated with the compound lost fat while showing no significant reduction in lean muscle mass.
"Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. "GLP-1s work almost entirely on the first, so we went after the second."
Reviving a Compound First Discovered Decades Ago
TOFA was initially discovered in the 1970s and belongs to a group of compounds known as ACC inhibitors. These compounds reduce the body's production of lipids.
Several ACC inhibitors have advanced into mid-stage clinical trials, but none has been approved to treat metabolic disease. One important obstacle is that many of these compounds can increase triglyceride levels, which may raise cardiovascular risk.
The UC Berkeley team found that TOFA behaves differently. In addition to acting as an ACC inhibitor, it activates PPARα and PPARδ, cellular receptors that switch on genes involved in taking up fat and burning it for energy.
In mice, this effect increased energy use by as much as 18% without causing the animals to become more physically active or increasing their body temperature. The researchers also found that TOFA did not produce the rise in triglycerides seen with some other ACC inhibitors, possibly because of its combined effects on lipid production and energy metabolism.
"TOFA appears to engage a coordinated metabolic response," said study first author Justin Y. Lee, a postdoctoral student at UCSF who conducted the research as a Ph.D. student at Berkeley. "It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively."
One Compound Outperformed a Two-Drug Approach
The researchers also tested whether they could reproduce TOFA's effects with two separate compounds. They gave mice one compound designed to suppress lipid production and another intended to increase energy expenditure.
That combination did not improve overall metabolic health as effectively as TOFA by itself, suggesting that TOFA's particular combination of actions may be important to its effects.
The team then examined whether TOFA could be paired with existing GLP-1 medications. These included semaglutide, sold under the brand names Ozempic or Wegovy, and tirzepatide, sold as Mounjaro and Zepbound.
In mice, combining TOFA with these GLP-1 drugs produced larger improvements in body weight, glucose control, insulin levels, and triglycerides than either treatment produced on its own.
"In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement," Näär said.
Human Testing Is Still Needed
Despite the promising results, the researchers emphasize that TOFA has so far been studied only in animals. Its safety and effectiveness in humans remain unknown and will need to be evaluated in future studies.
With support from Berkeley's life sciences entrepreneurship ecosystem, including Nucleate and Berkeley SkyDeck, the researchers have created a company called ReRx Therapeutics to help move the research toward potential use in patients.
The research was funded through discretionary funds from UC Berkeley, with additional assistance from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core.
Additional authors include Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang and Kook Son of Berkeley; Gracia Bonilla, Kashish Chetal and Ruslan I. Sadreyev of Massachusetts General Hospital; Kosuke Watari and Michael Karin of the University of California, San Diego; Christina Papa and Bilal N. Sheikh of the Helmholtz Center Munich; Prabha Ibrahim of ReRx Therapeutics.
Story Source:
Materials provided by University of California - Berkeley. Note: Content may be edited for style and length.
Journal Reference:
- Justin Y. Lee, Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Gracia Bonilla, Kosuke Watari, Christina Papa, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang, Kook Son, Kashish Chetal, Prabha Ibrahim, Ruslan I. Sadreyev, Bilal N. Sheikh, Michael Karin, Anders M. Näär. A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders. Science Advances, 2026; 12 (34) DOI: 10.1126/sciadv.aed3119
Cite This Page:
University of California - Berkeley. "Experimental compound helps burn fat without muscle loss." ScienceDaily. ScienceDaily, 23 August 2026. . University of California - Berkeley. (2026, August 23). Experimental compound helps burn fat without muscle loss. ScienceDaily. Retrieved August 23, 2026 from www.sciencedaily.com/releases/2026/08/260823014953.htm University of California - Berkeley. "Experimental compound helps burn fat without muscle loss." ScienceDaily. www.sciencedaily.com/releases/2026/08/260823014953.htm (accessed August 23, 2026).Explore More
from ScienceDaily RELATED STORIES Scientists Solve the Mystery of a Brain “switch” That Can Trigger Weight Loss in Opposite Ways Aug. 15, 2026 Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, ... Your Brain May Be Wired to Regain Lost Weight Aug. 3, 2026 Weight loss is not simply a test of willpower. The human brain evolved to protect body fat during times of scarcity, and it can treat a previously higher weight as the new normal, triggering stronger ... People Taking GLP-1 Weight Loss Drugs Like Ozempic Started Moving Less June 14, 2026 People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily ... Ozempic and Similar Weight-Loss Drugs Linked to 30% Lower Breast Cancer Risk June 6, 2026 A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the ... Blockbuster Weight Loss Drugs Like Ozempic Deliver Big Results but Face Big Questions Feb. 11, 2026 Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide ... Genetic Evidence That Diabetes Drug GLP-1 Receptor Agonists Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle Feb. 24, 2025 Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), ... TRENDING AT SCITECHDAILY.comA 47-Year-Old Scientist Tracked Himself for Months – His Biological Age Fell to 32
Astronomers Detect a Record-Breaking “Cosmic Laser” From 8 Billion Light-Years Away
Almost All Plant-Based Meat Alternatives Contain Mycotoxins, Study Finds
Just 4 Minutes of Daily Strength Training Can Quadruple Fitness in Older Adults
Print Email ShareBreaking
this hour- A Tiny Big Bang Leaves a Strange Clue
- A Hidden “On Switch” in Human DNA
- Burn Fat Without Losing Muscle
- Vitamin D Linked to Better Cognition
- Black Holes Keep Tearing These Stars Apart
- 400-Year-Old Shark Eyes Defy Aging
- Speaking More Languages May Slow Aging
- JWST Finds Hidden Mass in Early Galaxies
- Natural Supplement May Boost Cancer Immunity
- Queen Bees Pass Pesticides to Their Eggs
Trending Topics
this week HEALTH & MEDICINE Pharmacology Workplace Health Nutrition MIND & BRAIN Intelligence Perception Behavior LIVING & WELL Nutrition Behavior Gender DifferenceStrange & Offbeat
HEALTH & MEDICINE This Shark Can Live 400 Years. Its Eyes Barely Seem to Age Tooth Count May Predict Survival After Pancreatic Cancer Surgery This Gut Microbe May Help Keep You Strong as You Age MIND & BRAIN Mysterious Waves Sweeping Across Your Brain May Help Turn Sensory Chaos Into What You See Ozempic May Have Revealed the Brain’s Hidden “craving Center” The Adult Brain Can Repair Itself Better Than Scientists Thought LIVING & WELL COVID-19 Awakens Dormant Viruses — and One Is Linked to Long COVID When Gut Microbes Run Low on Fiber, They May Start Eating You Scientists Say Just 7 Days of Meditation Can Rewire Your Brain\n
